NEWS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
Sutro Biopharma Announces the Appointment of Diana Landa as Vice President of Regulatory Affairs and Annie Chang as Head of Investor Relations
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
Sutro Biopharma to Participate in Four Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development, and manufacturing company, today announced that Chief Executive Officer, Bill Newell, will participate in four upcoming virtual conferences...
ADC Review – Onco’Zine
Annual World ADC – Best New Drug Developer 2020: Sutro Biopharma’s Journey to Success https://www.adcreview.com/opinion/annual-world-adc-best-new-drug-developer-2020-sutro-biopharmas-journey-to-success/ William J. Newell Published Nov. 5, 2020 From liquid...
Sutro Biopharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights and Developments
- KOL Discussion of STRO-002 Data Event scheduled for December 3rd - Interim Phase 1 data from STRO-001 for patients with NHL will be presented at ASH - Milestone payment received from EMD Serono collaboration on MUC1-EGFR bispecific ADC - Honored as Best New Drug...
American Society of Hematology Conference 2020 – STRO-001 – Abstract
To view the abstract on ASH click here, ASH Website Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-cell Non-Hodgkin Lymphoma Nirav N. Shah1, Ahmad Mattour2, Leslie...
Sutro Biopharma Named Best New Drug Developer at the 7th Annual World ADC
SOUTH SAN FRANCISCO, Calif., Sept. 21, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company today announced that it has been recognized as Best New Drug Developer at the World ADC Digital Awards, held...
Sutro Biopharma Presents at World ADC 2020 – PowerPoint Presentation
To download the World ADC presentation by Arturo Molina, MD, MS, Chief Medical Officer, CLICK HERE To download the World ADC presentation by Trevor Hallam, Ph.D., Chief Scientific Officer, CLICK HERE To download the World ADC presentation by Shabbir Anik, Ph.D.,...
Cantor Fitzgerald Virtual Heathcare Conference 2020 – PowerPoint Presentation
To download the presentation, Click Here
STRO-002 Shows Early Efficacy, Safety in Heavily Pretreated Epithelial Ovarian Cancer – OncLive September 2020
The novel anti-folate receptor alpha antibody-drug conjugate STRO-002 demonstrated encouraging efficacy with a tolerable safety profile in patients with advanced platinum-resistant or refractory epithelial ovarian cancer. The novel anti-folate receptor alpha (FolRα)...
International Gynecologic Cancer Society (IGCS) Virtual Healthcare Conference 2020 – Poster
Phase 1 Dose-Escalation Study of STRO-002, An Anti-Folate Receptor Alpha (FRα) Antibody Drug Conjugate (ADC), in Patients with Advanced Platinum-Resistant/Refractory Epithelial Ovarian Cancer (OC)
